Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Hepatocellular × Methylprednisolone × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia 31 Lymphoma 25 Precursor Cell Lymphoblastic Leukemia-Lymphoma 24 Burkitt Lymphoma 23 Lymphoma, Non-Hodgkin 20 Lymphoma, Large B-Cell, Diffuse 20 Myelodysplastic Syndromes 18 Leukemia, Myeloid, Chronic-Phase 17 Lymphoma, Follicular 16 Leukemia, Lymphocytic, Chronic, B-Cell 15 Multiple Myeloma 14 Leukemia, Myeloid, Accelerated Phase 14 Blast Crisis 14 Lymphoma, Large-Cell, Immunoblastic 13 Dendritic Cell Sarcoma, Interdigitating 13 Recurrence 12 Myeloproliferative Disorders 12 Leukemia, Myeloid, Acute 12 Leukemia, Myelomonocytic, Chronic 11 Graft vs Host Disease 11 Lymphoma, Mantle-Cell 10 Lymphoma, B-Cell, Marginal Zone 10 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 10 Neoplasms, Plasma Cell 9 Myelodysplastic-Myeloproliferative Diseases 8 Leukemia, Myelomonocytic, Juvenile 8 Hodgkin Disease 8 Congenital Abnormalities 8 Primary Myelofibrosis 7 Lymphoma, Large-Cell, Anaplastic 7

Interventions

Sorafenib 62 Bevacizumab 59 lenvatinib 52 durvalumab 35 atezolizumab 27 sintilimab 26 Nivolumab 26 pembrolizumab 24 Oxaliplatin 24 tremelimumab 22 tislelizumab 22 Fluorouracil 21 apatinib 20 Radiosurgery 19 camrelizumab 18 regorafenib 15 cabozantinib 15 Doxorubicin 15 Leucovorin 14 Capecitabine 13 Radiotherapy 12 Folfox protocol 12 donafenib 11 Gemcitabine 10 Cisplatin 10 Immune Checkpoint Inhibitors 9 Erlotinib Hydrochloride 9 toripalimab 8 Neoadjuvant Therapy 8 Immunotherapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01726465 2013-11-13

MENHIR

Istituto Clinico Humanitas

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡